View in EDS

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

Saved in:
Bibliographic Details
Title: Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
Authors: Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Li T; Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Ogayo ER; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Rahman T; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., DiLullo MK; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Patel A; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., El-Refai S; Personalis Inc., Fremont, California., Abbott C; Personalis Inc., Fremont, California., Li B; Personalis Inc., Fremont, California., Boyle SM; Personalis Inc., Fremont, California., Chen RO; Personalis Inc., Fremont, California., Desai NV; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Spring LM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston., Tung NM; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Sinclair N; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Faggen M; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Constantine M; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., King TA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Krop IE; Yale Cancer Center, New Haven, Connecticut., Tayob N; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Winer EP; Yale Cancer Center, New Haven, Connecticut., Parsons HA; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Source: JAMA oncology [JAMA Oncol] 2026 Jun 25. Date of Electronic Publication: 2026 Jun 25.
Publication Type: Journal Article
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42348190
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Tarantino+P%22">Tarantino P</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Li+T%22">Li T</searchLink>; Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Ogayo+ER%22">Ogayo ER</searchLink>; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Rahman+T%22">Rahman T</searchLink>; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22DiLullo+MK%22">DiLullo MK</searchLink>; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Patel+A%22">Patel A</searchLink>; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22El-Refai+S%22">El-Refai S</searchLink>; Personalis Inc., Fremont, California.<br /><searchLink fieldCode="AU" term="%22Abbott+C%22">Abbott C</searchLink>; Personalis Inc., Fremont, California.<br /><searchLink fieldCode="AU" term="%22Li+B%22">Li B</searchLink>; Personalis Inc., Fremont, California.<br /><searchLink fieldCode="AU" term="%22Boyle+SM%22">Boyle SM</searchLink>; Personalis Inc., Fremont, California.<br /><searchLink fieldCode="AU" term="%22Chen+RO%22">Chen RO</searchLink>; Personalis Inc., Fremont, California.<br /><searchLink fieldCode="AU" term="%22Desai+NV%22">Desai NV</searchLink>; Beth Israel Deaconess Medical Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Spring+LM%22">Spring LM</searchLink>; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.<br /><searchLink fieldCode="AU" term="%22Tung+NM%22">Tung NM</searchLink>; Beth Israel Deaconess Medical Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Sinclair+N%22">Sinclair N</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Faggen+M%22">Faggen M</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Constantine+M%22">Constantine M</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22King+TA%22">King TA</searchLink>; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Krop+IE%22">Krop IE</searchLink>; Yale Cancer Center, New Haven, Connecticut.<br /><searchLink fieldCode="AU" term="%22Tayob+N%22">Tayob N</searchLink>; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Mittendorf+EA%22">Mittendorf EA</searchLink>; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Tolaney+SM%22">Tolaney SM</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Winer+EP%22">Winer EP</searchLink>; Yale Cancer Center, New Haven, Connecticut.<br /><searchLink fieldCode="AU" term="%22Parsons+HA%22">Parsons HA</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Waks+AG%22">Waks AG</searchLink>; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101652861%22">JAMA oncology</searchLink> [JAMA Oncol] 2026 Jun 25. <i>Date of Electronic Publication: </i>2026 Jun 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Medical+Association%22">American Medical Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101652861 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2374-2445 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223742437%22">23742437 </searchLink><i>NLM ISO Abbreviation: </i>JAMA Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42348190
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1001/jamaoncol.2026.2023
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tarantino P
      – PersonEntity:
          Name:
            NameFull: Li T
      – PersonEntity:
          Name:
            NameFull: Ogayo ER
      – PersonEntity:
          Name:
            NameFull: Rahman T
      – PersonEntity:
          Name:
            NameFull: DiLullo MK
      – PersonEntity:
          Name:
            NameFull: Patel A
      – PersonEntity:
          Name:
            NameFull: El-Refai S
      – PersonEntity:
          Name:
            NameFull: Abbott C
      – PersonEntity:
          Name:
            NameFull: Li B
      – PersonEntity:
          Name:
            NameFull: Boyle SM
      – PersonEntity:
          Name:
            NameFull: Chen RO
      – PersonEntity:
          Name:
            NameFull: Desai NV
      – PersonEntity:
          Name:
            NameFull: Spring LM
      – PersonEntity:
          Name:
            NameFull: Tung NM
      – PersonEntity:
          Name:
            NameFull: Sinclair N
      – PersonEntity:
          Name:
            NameFull: Faggen M
      – PersonEntity:
          Name:
            NameFull: Constantine M
      – PersonEntity:
          Name:
            NameFull: King TA
      – PersonEntity:
          Name:
            NameFull: Krop IE
      – PersonEntity:
          Name:
            NameFull: Tayob N
      – PersonEntity:
          Name:
            NameFull: Mittendorf EA
      – PersonEntity:
          Name:
            NameFull: Tolaney SM
      – PersonEntity:
          Name:
            NameFull: Winer EP
      – PersonEntity:
          Name:
            NameFull: Parsons HA
      – PersonEntity:
          Name:
            NameFull: Waks AG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 06
              Text: 2026 Jun 25
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2374-2445
          Titles:
            – TitleFull: JAMA oncology
              Type: main
ResultId 1